Loading...

Home
Stock
ABBV

ABBV Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

213.490

Open

211.420

VWAP

210.67

Vol

5.65M

Mkt Cap

370.38B

Low

209.120

Amount

1.19B

EV/EBITDA(TTM)

14.68

Total Shares

1.77B

EV

432.66B

EV/OCF(TTM)

22.74

P/S(TTM)

6.07

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Show More

Events Timeline

(ET)

2026-03-24

08:10:00

AbbVie Partners with MLB for Multi-Year Deal

2026-03-17 (ET)

2026-03-17

06:20:00

Alloy Therapeutics Signs Antibody Platform Development Agreement with AbbVie

2026-03-16 (ET)

2026-03-16

08:20:00

Allergan Aesthetics Launches Skin Quality Index

2026-03-09 (ET)

2026-03-09

08:10:00

AbbVie Reports Positive Results for ABBV-295 Clinical Trial

2026-03-02 (ET)

2026-03-02

12:00:00

AbbVie's Neuroendocrine Carcinoma Treatment Receives FDA Orphan Designation

2026-03-02

08:40:00

AbbVie Reports Positive Results from Crohn's Disease Study

2026-02-26 (ET)

2026-02-26

10:20:00

AtaiBeckley Reports Phase 2 Results for EMP-01 in Social Anxiety Disorder

2026-02-23 (ET)

2026-02-23

11:10:00

AbbVie Announces $380M Investment for New Drug Manufacturing Facilities

News

PRnewswire

03-27PRnewswire

PinnedAbbVie Advances Dermatology Research at AAD 2026

Research Presentation: AbbVie will present 24 research abstracts at the 2026 American Academy of Dermatology Annual Meeting, including a significant late-breaking study that underscores the company's leadership in advancing treatment standards for immune-mediated skin diseases, which is expected to reshape future treatment paradigms.
Long-Term Efficacy Data: The KEEPsAKE 1 Phase 3 trial shows that risankizumab maintains radiographic non-progression in patients with active psoriatic arthritis over five years, indicating its potential to significantly improve patient quality of life.
Safety Studies: Long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis from three Phase 3 studies reveal six years of results, further solidifying its application prospects and potentially enhancing market acceptance.
Real-World Evidence: The AD-VISE study provides real-world effectiveness data for upadacitinib across different body regions, highlighting its importance in patient-reported outcomes, which may influence prescribing decisions and treatment choices among physicians.

Fool

Eli Lilly Faces Competitive Pressure but Maintains Optimistic Outlook

Market Performance: Despite leading the weight-loss medicine market, Eli Lilly's shares have fallen 15% this year, raising concerns about intensified competition in its core niche that could erode pricing power and profits.
Margin Improvement: Since 2020, Eli Lilly's gross and operating margins have significantly improved, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced manufacturing efficiency.
Manufacturing Capacity Investment: Eli Lilly has invested $55 billion since 2020 to expand its manufacturing capacity, which may hurt profits and margins in the short term but is expected to lower costs and boost capacity, driving significant economies of scale in the long run.
Artificial Intelligence Initiatives: Eli Lilly has built the largest supercomputer in the pharmaceutical industry with Nvidia's help, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially having a positive impact across the business.

NASDAQ.COM

03-28NASDAQ.COM

Eli Lilly's Competitive Margin Analysis

Margin Improvement: Since 2020, Eli Lilly has significantly improved its gross and operating margins, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced drug manufacturing efficiency.
Competitive Market Pressure: Despite leading the weight-loss drug market, Eli Lilly's shares have fallen 15% this year, raising concerns about potential fierce competition that could erode pricing power and profits in the future.
Manufacturing Capacity Investment: Eli Lilly has invested $55 billion in expanding its manufacturing capacity since 2020, which may hurt profits in the short term but is expected to lower costs and enhance economies of scale in the long run.
Artificial Intelligence Applications: Eli Lilly has partnered with Nvidia to build the largest supercomputer in the pharmaceutical industry, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially benefiting the entire business.

NASDAQ.COM

03-27NASDAQ.COM

AbbVie Increases Dividend by Over 330% Since 2013

Significant Dividend Growth: AbbVie has increased its dividend by over 330% since 2013, which not only enhances investor income expectations but also boosts the company's market appeal, reflecting its stable cash flow and profitability.
Strong Revenue Growth: Despite losing patent protection for Humira, AbbVie reported an 8.6% year-over-year revenue increase in 2025, indicating the resilience of its product portfolio and sustained market demand, further solidifying its position in the pharmaceutical industry.
Robust R&D Pipeline: With over 90 drugs currently in development, AbbVie's extensive pipeline not only secures future revenue growth but also demonstrates the company's ongoing commitment to innovation and strategic planning in drug development.
Reasonable Valuation Levels: AbbVie’s forward-looking P/E ratio stands at 14, slightly above the five-year average of 13, suggesting that the market's growth expectations are reasonable while providing investors with a relatively attractive entry point.

Fool

AbbVie: A Reliable Source of Dividend Income

Dividend Yield Advantage: AbbVie boasts a dividend yield of 3.38%, significantly higher than the S&P 500 average of 1.1%, making it an ideal choice for income-seeking investors looking to cover living expenses or reinvest.
Dividend Payment Capability: With a recent dividend of $1.73 per share, translating to an annual payout of $6.92, investors aiming for $10,000 in annual dividends would need to purchase 1,445 shares, costing approximately $296,225, highlighting its reliable dividend payment.
Consistent Dividend Growth: AbbVie has increased its dividend by over 330% since 2013, and when combined with Abbott's history, it has achieved annual dividend growth for over 25 years, showcasing its appeal as a long-term investment.
Strong Growth Potential: Despite losing patent protection for its blockbuster drug Humira, AbbVie’s 2025 revenue still grew by 8.6% year-over-year, and its pipeline of over 90 drugs in development indicates promising future growth, further enhancing its investment value.

CNBC

White House Hosts First Humanoid Robot Guest

High-Profile Showcase: The White House hosted its first humanoid robot, Figure 3, during the Global Coalition Summit, showcasing advancements in U.S. humanoid robotics and highlighting the technology's significance in global tech competition, likely boosting brand recognition for Figure AI.
Educational Potential: Melania Trump promoted the use of the robot for AI in children's education, suggesting that such robots could become interactive educators at home, which could significantly enhance the technological aspect of family education and its societal implications.
Funding and Valuation: Figure AI raised over $1 billion in its Series C funding round in September, achieving a post-money valuation of $39 billion, with plans to deploy thousands of robots in homes and logistics, reflecting strong investor enthusiasm for physical AI.
Legal Risk Awareness: The ongoing lawsuit against Figure AI may be reexamined due to Melania's endorsement, as a former safety head alleged safety concerns regarding the robots, emphasizing the need for safety standards in humanoid robotics development, which could impact the company's reputation and future growth.

Wall Street analysts forecast ABBV stock price to rise

18 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise

12 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

RBC Capital

Trung Huynh

Outperform

initiated

$260

AI Analysis

2026-02-24

Reason

RBC Capital

Trung Huynh

Price Target

$260

AI Analysis

2026-02-24

initiated

Outperform

Reason

RBC Capital analyst Trung Huynh initiated coverage of AbbVie with an Outperform rating and $260 price target. The shares have underperformed on concerns AbbVie's "beat-and-raise" story is over and competition threatens its immunology growth, the analyst tells investors in a research note. RBC disagrees, saying AbbVie is still in early in indication expansion. It sees continued outperformance for the shares.

Barclays

Strong Buy

initiated

$275

2026-02-19

Reason

Barclays

Price Target

$275

2026-02-19

initiated

Strong Buy

Reason

Barclays initiated coverage of AbbVie with an Overweight rating and $275 price target. The firm believes consensus estimates are underestimating AbbVie's operating leverage potential. Barclays believes success in any of AbbVie's proof-of-concept studies can drive multiple expansion for the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 16.63, compared to its 5-year average forward P/E of 13.17. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

13.17

Current PE

16.63

Overvalued PE

15.95

Undervalued PE

10.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

12.18

Current EV/EBITDA

14.93

Overvalued EV/EBITDA

14.14

Undervalued EV/EBITDA

10.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.92

Current PS

6.25

Overvalued PS

5.75

Undervalued PS

4.09

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Find me a trade a d take i

Intellectia · 85 candidates

Region: USVolume: >= -100List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceCrossDownMA20, PriceAboveMA20, PriceAboveMA200, PriceBelowMA20, PriceBelowMA200Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceFallBelowSupport, PriceAroundResistance, PriceAroundSupportOne Day Rise Prob: 0 - 100One Day Predict Return: 0.0% - 100.0%One Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= -100Macd: positive, negative, bearish, bullish

Ticker

Name

Market Cap$

AbbVie Inc

362.35B

Abbott Laboratories

182.61B

Arm Holdings PLC

145.38B

Anheuser-Busch Inbev SA

133.72B

British American Tobacco plc

125.56B

Adobe Inc

100.95B

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

Eli Lilly and Co

866.87B

AbbVie Inc

364.65B

AstraZeneca PLC

293.00B

Merck & Co Inc

282.35B

UnitedHealth Group Inc

254.55B

Amgen Inc

188.63B

best stocks to swing trade

Intellectia · 1222 candidates

Region: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $-5.00 - $40.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

Exxon Mobil Corp

635.43B

Costco Wholesale Corp

448.66B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

General Electric Co

358.95B

Intellectia · 59 candidates

Market Cap: >= 80.00BDividend Yield Ttm: 1 - 6Net Margin: >= 5.00Return On Equity: >= 10.0%Is Index Component: GSPC, DJI

Ticker

Name

Market Cap$

JPMorgan Chase & Co

809.92B

Exxon Mobil Corp

635.43B

Johnson & Johnson

598.69B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

Home Depot Inc

379.01B

Stocks with same technicals as DHR

Intellectia · 52 candidates

Market Cap: >= 150.00BRegion: USRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.31T

Apple Inc

3.88T

Alphabet Inc

3.77T

Broadcom Inc

1.52T

Tesla Inc

1.51T

Walmart Inc

1.02T

which are the s&p 500 companies

Intellectia · 476 candidates

Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.61T

Apple Inc

3.88T

Alphabet Inc

3.81T

Microsoft Corp

2.95T

Amazon.com Inc

2.26T

Meta Platforms Inc

1.66T

medical and tech

Intellectia · 1801 candidates

Sector: Financial Technology (Fintech) & Infrastructure, Healthcare, Healthcare Services & Equipment, Technology, Technology EquipmentList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

NVIDIA Corp

4.57T

Apple Inc

3.88T

Alphabet Inc

3.68T

Microsoft Corp

2.97T

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Meta Platforms Inc

1.63T

pe > 10 and macd golden cross

Intellectia · 1278 candidates

Pe Ttm: >= 10Macd: bullish

Ticker

Name

Market Cap$

Apple Inc

4.02T

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Broadcom Inc

1.61T

Berkshire Hathaway Inc

1.08T

Berkshire Hathaway Inc

1.08T

JPMorgan Chase & Co

866.44B

stocks to buy Monday

Intellectia · 297 candidates

Market Cap: >= 2.00BPrice: $5.00 - $300.00Quarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: >= 10.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

NVIDIA Corp

4.49T

Apple Inc

4.07T

AbbVie Inc

395.82B

Advanced Micro Devices Inc

339.29B

AstraZeneca PLC

298.88B

Morgan Stanley

285.91B

stocks with congressional trading data

Intellectia · 158 candidates

Congress Transactions: sale, purchase

Ticker

Name

Market Cap$

NVIDIA Corp

4.64T

Alphabet Inc

4.09T

Apple Inc

3.81T

Microsoft Corp

3.20T

Amazon.com Inc

2.56T

Meta Platforms Inc

1.81T

Whales Holding ABBV

Caisse des Dépôts et Consignations

Mubadala Investment Company PJSC

Journey Strategic Wealth LLC

Eagle Global Advisors, LLC

Middlefield Capital Corporation

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 209.4 USD — it has decreased -0.81

What is AbbVie Inc (ABBV)'s business?

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is252.00 USD with a low forecast of 223.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 16.62B USD, increased 10.04

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 1.02 USD, decreased -5200.00

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 57000 emplpoyees as of March 30 2026.

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 370.38B USD.